MitoSense

Executive Summary

MitoSense is a preclinical-stage biotechnology company developing a novel mitochondrial replacement therapy to combat neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s. Its proprietary, patent-pending technology aims to replenish dysfunctional mitochondria in cells, restoring cellular energy metabolism and potentially halting or reversing disease progression. The company was founded in 2017 and is based in San Diego, California. By targeting the root cause of mitochondrial dysfunction, MitoSense's approach has the potential to address a broad range of disorders that currently lack disease-modifying treatments. While still in early development, MitoSense holds exclusive licenses to foundational intellectual property and is actively advancing its lead candidate toward the clinic. The company's success hinges on demonstrating proof-of-concept in animal models and securing funding for IND-enabling studies. If successful, MitoSense could represent a paradigm shift in treating neurodegeneration, offering a first-in-class therapy for millions of patients worldwide. However, significant technical and regulatory hurdles remain, and the company has not yet disclosed specific pipeline milestones or financing details.

Upcoming Catalysts (preview)

• Q3 2026Initial preclinical efficacy data in an ALS mouse model40% success
• Q4 2026Series A financing round completion50% success
• Q2 2027IND filing for lead candidate in Alzheimer's disease30% success